Is H19 RNA a Useful Marker of Acromegaly and Its Complications? A Preliminary Study
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. H19 Expression
3.2. Comorbidities
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Katznelson, L.; Laws, E.R.; Melmed, S.; Molitch, M.E.; Murad, M.H.; Utz, A.; Wass, J.A.H. Acromegaly: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2014, 99, 3933–3951. [Google Scholar] [CrossRef] [PubMed]
- Inoshita, N.; Nishioka, H. The 2017 WHO Classification of Pituitary Adenoma: Overview and Comments. Brain Tumor Pathol. 2018, 35, 51–56. [Google Scholar] [CrossRef] [PubMed]
- Ho, K.; Fleseriu, M.; Kaiser, U.; Salvatori, R.; Brue, T.; Lopes, M.B.; Kunz, P.; Molitch, M.; Camper, S.A.; Gadelha, M.; et al. Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? J. Endocr. Soc. 2021, 5, bvaa205. [Google Scholar] [CrossRef] [PubMed]
- Ershadinia, N.; Tritos, N.A. Diagnosis and Treatment of Acromegaly: An Update. Mayo Clin. Proc. 2022, 97, 333–346. [Google Scholar] [CrossRef]
- Giustina, A.; Barkhoudarian, G.; Beckers, A.; Ben-Shlomo, A.; Biermasz, N.; Biller, B. Multidisciplinary Management of Acromegaly: A Consensus. Rev. Endocr. Metab. Disord. 2020, 21, 667–678. [Google Scholar] [CrossRef]
- Gadelha, M.R.; Kasuki, L.; Lim, D.S.T.; Fleseriu, M. Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. Endocr. Rev. 2019, 40, 268–332. [Google Scholar] [CrossRef]
- Pivonello, R.; Auriemma, R.S.; Grasso, L.F.S.; Pivonello, C.; Simeoli, C.; Patalano, R.; Galdiero, M.; Colao, A. Complications of Acromegaly: Cardiovascular, Respiratory and Metabolic Comorbidities. Pituitary 2017, 20, 46–62. [Google Scholar] [CrossRef]
- Abreu, A.; Tovar, A.P.; Castellanos, R.; Valenzuela, A.; Giraldo, C.M.G.; Pinedo, A.C.; Guerrero, D.P.; Barrera, C.A.B.; Franco, H.I.; Ribeiro-Oliveira, A.; et al. Challenges in the Diagnosis and Management of Acromegaly: A Focus on Comorbidities. Pituitary 2016, 19, 448–457. [Google Scholar] [CrossRef]
- Ponting, C.P.; Oliver, P.L.; Reik, W. Evolution and Functions of Long Noncoding RNAs. Cell 2009, 136, 629–641. [Google Scholar] [CrossRef]
- Zhang, P.; Wu, W.; Chen, Q.; Chen, M. Non-Coding RNAs and Their Integrated Networks. J. Integr. Bioinform. 2019, 16, 20190027. [Google Scholar] [CrossRef]
- Shi, X.; Sun, M.; Liu, H.; Yao, Y.; Song, Y. Long Non-Coding RNAs: A New Frontier in the Study of Human Diseases. Cancer Lett. 2013, 339, 159–166. [Google Scholar] [CrossRef] [PubMed]
- Pachnis, V.; Belayew, A.; Tilghman, S.M. Locus Unlinked to Alpha-Fetoprotein under the Control of the Murine Raf and Rif Genes. Proc. Natl. Acad. Sci. USA 1984, 81, 5523–5527. [Google Scholar] [CrossRef]
- Yoshimura, H.; Matsuda, Y.; Yamamoto, M.; Kamiya, S.; Ishiwata, T. Expression and Role of Long Non-Coding RNA H19 in Carcinogenesis. Front. Biosci. Landmark 2018, 23, 614–625. [Google Scholar] [CrossRef]
- Ariel, I.; Ayesh, S.; Perlman, E.; Pizov, G.; Tanos, V.; Schneider, T.; Erdmann, V.; Podeh, D.; Komitowski, D.; Quasem, A.; et al. The Product of the Imprinted H19 Gene Is an Oncofetal RNA. Mol. Pathol. 1997, 50, 34–44. [Google Scholar] [CrossRef]
- Bartolomei, M.S.; Zemel, S.; Tilghman, S.M. Parental Imprinting of the Mouse H19 Gene. Nature 1991, 351, 153–155. [Google Scholar] [CrossRef]
- Hibi, K.; Nakamura, H.; Hirai, A.; Fujikake, Y.; Kasai, Y.; Akiyama, S.; Ito, K.; Takagi, H. Loss of H19 Imprinting in Esophageal Cancer. Cancer Res. 1996, 56, 480–482. [Google Scholar]
- Kondo, M.; Suzuki, H.; Ueda, R.; Osada, H.; Takagi, K.; Takahashi, T. Frequent Loss of Imprinting of the H19 Gene Is Often Associated with Its Overexpression in Human Lung Cancers. Oncogene 1995, 10, 1193–1198. [Google Scholar]
- Wu, B.; Zhang, Y.; Yu, Y.; Zhong, C.; Lang, Q.; Liang, Z.; Lv, C.; Xu, F.; Tian, Y. Long Noncoding RNA H19: A Novel Therapeutic Target Emerging in Oncology Via Regulating Oncogenic Signaling Pathways. Front. Cell. Dev. Biol. 2021, 9, 796740. [Google Scholar] [CrossRef]
- Li, H.; Yu, B.; Li, J.; Su, L.; Yan, M.; Zhu, Z.; Liu, B. Overexpression of LncRNA H19 Enhances Carcinogenesis and Metastasis of Gastric Cancer. Oncotarget 2014, 5, 2318–2329. [Google Scholar] [CrossRef]
- Verkerk, A.J.; Ariel, I.; Dekker, M.C.; Schneider, T.; van Gurp, R.J.; de Groot, N.; Gillis, A.J.; Oosterhuis, J.W.; Hochberg, A.A.; Looijenga, L.H. Unique Expression Patterns of H19 in Human Testicular Cancers of Different Etiology. Oncogene 1997, 14, 95–107. [Google Scholar] [CrossRef]
- Berteaux, N.; Lottin, S.; Monté, D.; Pinte, S.; Quatannens, B.; Coll, J.; Hondermarck, H.; Curgy, J.J.; Dugimont, T.; Adriaenssens, E. H19 MRNA-like Noncoding RNA Promotes Breast Cancer Cell Proliferation through Positive Control by E2F1. J. Biol. Chem. 2005, 280, 29625–29636. [Google Scholar] [CrossRef] [PubMed]
- Qian, B.; Wang, D.M.; Gu, X.S.; Zhou, K.; Wu, J.; Zhang, C.Y.; He, X.Y. LncRNA H19 Serves as a CeRNA and Participates in Non-Small Cell Lung Cancer Development by Regulating MicroRNA-107. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 5946–5953. [Google Scholar] [CrossRef] [PubMed]
- Moulton, T.; Crenshaw, T.; Hao, Y.; Moosikasuwan, J.; Lin, N.; Dembitzer, F.; Hensle, T.; Weiss, L.; McMorrow, L.; Loew, T.; et al. Epigenetic Lesions at the H19 Locus in Wilms’ Tumour Patients. Nat. Genet. 1994, 7, 440–447. [Google Scholar] [CrossRef]
- Gicquel, C.; Raffin-Sanson, M.-L.; Gaston, V.; Bertagna, X.; Plouin, P.-F.; Schlumberger, M.; Louvel, A.; Luton, J.-P.; le Bouc, Y. Structural and Functional Abnormalities at 11p15 Are Associated with the Malignant Phenotype in Sporadic Adrenocortical Tumors: Study on a Series of 82 Tumors. J. Clin. Endocrinol. Metab. 1997, 82, 2559–2565. [Google Scholar] [CrossRef]
- Shima, H.; Kida, K.; Adachi, S.; Yamada, A.; Sugae, S.; Narui, K.; Miyagi, Y.; Nishi, M.; Ryo, A.; Murata, S.; et al. Lnc RNA H19 Is Associated with Poor Prognosis in Breast Cancer Patients and Promotes Cancer Stemness. Breast Cancer Res. Treat. 2018, 170, 507–516. [Google Scholar] [CrossRef]
- Si, H.; Chen, P.; Li, H.; Wang, X. Long Non-Coding RNA H19 Regulates Cell Growth and Metastasis via MiR-138 in Breast Cancer. Am. J. Transl. Res. 2019, 11, 3213–3225. [Google Scholar]
- Luo, J.; Li, Q.; Pan, J.; Li, L.; Fang, L.; Zhang, Y. Expression Level of Long Noncoding RNA H19 in Plasma of Patients with Nonsmall Cell Lung Cancer and Its Clinical Significance. J. Cancer Res. Ther. 2018, 14, 860–863. [Google Scholar] [CrossRef]
- Huang, C.; Cao, L.; Qiu, L.; Dai, X.; Ma, L.; Zhou, Y.; Li, H.; Gao, M.; Li, W.; Zhang, Q.; et al. Upregulation of H19 Promotes Invasion and Induces Epithelial-to-Mesenchymal Transition in Esophageal Cancer. Oncol. Lett. 2015, 10, 291–296. [Google Scholar] [CrossRef]
- Tsang, W.P.; Ng, E.K.; Ng, S.S.; Jin, H.; Yu, J.; Sung, J.J.; Kwok, T.T. Oncofetal H19-Derived MiR-675 Regulates Tumor Suppressor RB in Human Colorectal Cancer. Carcinogenesis 2010, 31, 350–358. [Google Scholar] [CrossRef]
- Zhong, M.E.; Chen, Y.; Zhang, G.; Xu, L.; Ge, W.; Wu, B. LncRNA H19 Regulates PI3K-Akt Signal Pathway by Functioning as a CeRNA and Predicts Poor Prognosis in Colorectal Cancer: Integrative Analysis of Dysregulated NcRNA-Associated CeRNA Network. Cancer Cell. Int. 2019, 19, 148. [Google Scholar] [CrossRef]
- Ariel, I.; Lustig, O.; Schneider, T.; Pizov, G.; Sappir, M.; De-Groot, N.; Hochberg, A. The Imprinted H19 Gene as a Tumor Marker in Bladder Carcinoma. Urology 1995, 45, 335–338. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Yang, K.; Yuan, W.; Gao, Z. Determination of Serum Exosomal H19 as a Noninvasive Biomarker for Bladder Cancer Diagnosis and Prognosis. Med. Sci. Monit. 2018, 24, 9307–9316. [Google Scholar] [CrossRef]
- Zhang, K.; Luo, Z.; Zhang, Y.; Zhang, L.; Wu, L.; Liu, L.; Yang, J.; Song, X.; Liu, J. Circulating LncRNA H19 in Plasma as a Novel Biomarker for Breast Cancer. Cancer Biomark. 2016, 17, 187–194. [Google Scholar] [CrossRef]
- Zhong, G.; Wang, K.; Li, J.; Xiao, S.; Wei, W.; Liu, J. Determination of Serum Exosomal H19 as a Noninvasive Biomarker for Breast Cancer Diagnosis. Onco Targets Ther. 2020, 13, 2563. [Google Scholar] [CrossRef]
- Zhang, Y.; Liu, Y.T.; Tang, H.; Xie, W.Q.; Yao, H.; Gu, W.T.; Zheng, Y.Z.; Shang, H.B.; Wang, Y.; Wei, Y.X.; et al. Exosome-Transmitted LncRNA H19 Inhibits the Growth of Pituitary Adenoma. J. Clin. Endocrinol. Metab. 2019, 104, 6345–6356. [Google Scholar] [CrossRef]
- Zhong, L.; Liu, P.; Fan, J.; Luo, Y. Long Non-Coding RNA H19: Physiological Functions and Involvements in Central Nervous System Disorders. Neurochem. Int. 2021, 148, 105072. [Google Scholar] [CrossRef]
- Wu, Z.R.; Yan, L.; Liu, Y.T.; Cao, L.; Guo, Y.H.; Zhang, Y.; Yao, H.; Cai, L.; Shang, H.B.; Rui, W.W.; et al. Inhibition of MTORC1 by LncRNA H19 via Disrupting 4E-BP1/Raptor Interaction in Pituitary Tumours. Nat. Commun. 2018, 9, 4624. [Google Scholar] [CrossRef]
- Wu, Z.; Zheng, Y.; Xie, W.; Li, Q.; Zhang, Y.; Ren, B.; Cai, L.; Cheng, Y.; Tang, H.; Su, Z.; et al. The Long Noncoding RNA-H19/MiRNA-93a/ATG7 Axis Regulates the Sensitivity of Pituitary Adenomas to Dopamine Agonists. Mol. Cell. Endocrinol. 2020, 518, 111033. [Google Scholar] [CrossRef]
- Zhou, L.; Wan, Y.; Cheng, Q.; Shi, B.; Zhang, L.; Chen, S. The Expression and Diagnostic Value of LncRNA H19 in the Blood of Patients with Osteoarthritis. Iran. J. Public Health 2020, 49, 1494–1501. [Google Scholar] [CrossRef]
- Chen, S.; Liu, D.; Zhou, Z.; Qin, S. Role of Long Non-Coding RNA H19 in the Development of Osteoporosis. Mol. Med. 2021, 27, 122. [Google Scholar] [CrossRef]
- Su, W.; Huo, Q.; Wu, H.; Wang, L.; Ding, X.; Liang, L.; Zhou, L.; Zhao, Y.; Dan, J.; Zhang, H. The Function of LncRNA-H19 in Cardiac Hypertrophy. Cell. Biosci. 2021, 11, 153. [Google Scholar] [CrossRef] [PubMed]
- Safaei, S.; Tahmasebi-Birgani, M.; Bijanzadeh, M.; Seyedian, S.M. Increased Expression Level of Long Noncoding RNA H19 in Plasma of Patients with Myocardial Infarction. Int. J. Mol. Cell. Med. 2020, 9, 122. [Google Scholar] [CrossRef] [PubMed]
- Alfaifi, M.; Verma, A.K.; Alshahrani, M.Y.; Joshi, P.C.; Alkhathami, A.G.; Ahmad, I.; Hakami, A.R.; Beg, M.M.A. Assessment of Cell-Free Long Non-Coding RNA-H19 and MiRNA-29a, MiRNA-29b Expression and Severity of Diabetes. Diabetes Metab. Syndr. Obes. 2020, 13, 3727–3737. [Google Scholar] [CrossRef] [PubMed]
- Fawzy, M.S.; Abdelghany, A.A.; Toraih, E.A.; Mohamed, A.M. Circulating Long Noncoding RNAs H19 and GAS5 Are Associated with Type 2 Diabetes but Not with Diabetic Retinopathy: A Preliminary Study. Bosn. J. Basic Med. Sci. 2020, 20, 365–371. [Google Scholar] [CrossRef]
- Bolanowski, M.; Ruchała, M.; Zgliczyński, W.; Kos-Kudła, B.; Hubalewska-Dydejczyk, A.; Lewiński, A. Diagnostics and Treatment of Acromegaly—Updated Recommendations of the Polish Society of Endocrinology. Endokrynol. Pol. 2019, 70, 2–18. [Google Scholar] [CrossRef]
- Mair, P.; Wilcox, R. Robust Statistical Methods in R Using the WRS2 Package. Behav. Res. Methods 2020, 52, 464–488. [Google Scholar] [CrossRef]
- Yballe, C.M.; Vu, T.H.; Hoffman, A.R. Imprinting and Expression of Insulin-like Growth Factor-II and H19 in Normal Breast Tissue and Breast Tumor. J. Clin. Endocrinol. Metab. 1996, 81, 1607–1612. [Google Scholar] [CrossRef]
- Arita, T.; Ichikawa, D.; Konishi, H.; Komatsu, S.; Shiozaki, A.; Shoda, K.; Kawaguchi, T.; Hirajima, S.; Nagata, H.; Kubota, T.; et al. Circulating Long Non-Coding RNAs in Plasma of Patients with Gastric Cancer. Anticancer Res. 2013, 33, 3185–3194. [Google Scholar]
- Yu, B.; Cui, R.; Lan, Y.; Zhang, J.; Liu, B. Long Non-Coding RNA H19 as a Diagnostic Marker in Peripheral Blood of Patients with Sepsis. Am. J. Transl. Res. 2021, 13, 2923–2930. [Google Scholar]
- Hashemian, F.; Ghafouri-Fard, S.; Arsang-Jang, S.; Mirzajani, S.; Fallah, H.; Mehvari Habibabadi, J.; Sayad, A.; Taheri, M. Epilepsy Is Associated with Dysregulation of Long Non-Coding RNAs in the Peripheral Blood. Front. Mol. Biosci. 2019, 6, 113. [Google Scholar] [CrossRef]
- Tello-Flores, V.A.; Valladares-Salgado, A.; Ramírez-Vargas, M.A.; Cruz, M.; del-Moral-Hernández, O.; Cahua-Pablo, J.Á.; Ramírez, M.; Hernández-Sotelo, D.; Armenta-Solis, A.; Flores-Alfaro, E. Altered Levels of MALAT1 and H19 Derived from Serum or Serum Exosomes Associated with Type-2 Diabetes. Noncoding RNA Res. 2020, 5, 71–76. [Google Scholar] [CrossRef]
- Lu, T.; Yu, C.; Ni, H.; Liang, W.; Yan, H.; Jin, W. Expression of the Long Non-Coding RNA H19 and MALAT-1 in Growth Hormone-Secreting Pituitary Adenomas and Its Relationship to Tumor Behavior. Int. J. Dev. Neurosci. 2018, 67, 46–50. [Google Scholar] [CrossRef]
- Zhu, Z.; Song, L.; He, J.; Sun, Y.; Liu, X.; Zou, X. Ectopic Expressed Long Non-Coding RNA H19 Contributes to Malignant Cell Behavior of Ovarian Cancer. Int. J. Clin. Exp. Pathol. 2015, 8, 10082–10091. [Google Scholar]
- Colao, A.; Ferone, D.; Marzullo, P.; Lombardi, G. Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocr. Rev. 2004, 25, 102–152. [Google Scholar] [CrossRef]
- Rolla, M.; Jawiarczyk-Przybyłowska, A.; Halupczok-Żyła, J.; Kałużny, M.; Konopka, B.M.; Błoniecka, I.; Zieliński, G.; Bolanowski, M. Complications and Comorbidities of Acromegaly—Retrospective Study in Polish Center. Front. Endocrinol. 2021, 12, 642131. [Google Scholar] [CrossRef]
- Tirosh, A.; Shimon, I. Complications of Acromegaly: Thyroid and Colon. Pituitary 2017, 20, 70–75. [Google Scholar] [CrossRef]
- Montini, M.; Gianola, D.; Pagani, M.D.; Pedroncelli, A.; Caldara, R.; Gherardi, F.; Bonelli, M.; Lancranjan, I.; Pagani, G. Cholelithiasis and Acromegaly: Therapeutic Strategies. Clin. Endocrinol. 1994, 40, 401–406. [Google Scholar] [CrossRef]
- Attanasio, R.; Mainolfi, A.; Grimaldi, F.; Cozzi, R.; Montini, M.; Carzaniga, C.; Grottoli, S.; Cortesi, L.; Albizzi, M.; Testa, R.M.; et al. Somatostatin Analogs and Gallstones: A Retrospective Survey on a Large Series of Acromegalic Patients. J. Endocrinol. Investig. 2008, 31, 704–710. [Google Scholar] [CrossRef]
- Gan, X.; Liu, S.; Liang, K. MicroRNA-19b-3p Promotes Cell Proliferation and Osteogenic Differentiation of BMSCs by Interacting with LncRNA H19. BMC Med. Genet. 2020, 21, 11. [Google Scholar] [CrossRef]
- Li, Z.; Hong, Z.; Zheng, Y.; Dong, Y.; He, W.; Yuan, Y.; Guo, J. An Emerging Potential Therapeutic Target for Osteoporosis: LncRNA H19/MiR-29a-3p Axis. Eur. J. Histochem. 2020, 64, 3155. [Google Scholar] [CrossRef]
- Zhang, Y.; Huang, W.; Yuan, Y.; Li, J.; Wu, J.; Yu, J.; He, Y.; Wei, Z.; Zhang, C. Long Non-Coding RNA H19 Promotes Colorectal Cancer Metastasis via Binding to HnRNPA2B1. J. Exp. Clin. Cancer Res. 2020, 39, 141. [Google Scholar] [CrossRef] [PubMed]
- Ding, D.; Li, C.; Zhao, T.; Li, D.; Yang, L.; Zhang, B. LncRNA H19/MiR-29b-3p/PGRN Axis Promoted Epithelial-Mesenchymal Transition of Colorectal Cancer Cells by Acting on Wnt Signaling. Mol. Cells 2018, 41, 423. [Google Scholar] [CrossRef] [PubMed]
Acromegaly (N = 32) | Controls (N = 25) | ||||||
---|---|---|---|---|---|---|---|
Mean ± SD | Median | IQR | Mean ± SD | Median | IQR | p | |
Sex (F%/M%) | 75/25 | 64/36 | 0.368 | ||||
Age (years) | 51.97 ± 13.93 | 48.00 | 43.00–64.50 | 41.08 ± 13.79 | 39.00 | 30.00–49.00 | 0.005 |
Height (cm) | 165.11 ± 8.51 | 164.00 | 158.5–170.5 | 170.17 ± 9.05 | 168.00 | 164.00–180.00 | 0.045 |
Weight (kg) | 84.43 ± 18.74 | 83.50 | 70.50–99.50 | 71.63 ± 18.36 | 69.00 | 57.00–82.00 | 0.018 |
BMI (m2/kg) | 30.92 ± 6.42 | 31.05 | 26.37–35.27 | 24.55 ± 5.14 | 24.54 | 19.37–29.39 | 0.001 |
IGF-I (ng/mL) | 275.31 ± 199.08 | 181.50 | 131.00–395.00 | 136.28 ± 54.29 | 138.00 | 93.70–153.00 | 0.004 |
IGF-I/ULN | 1.12 ± 0.78 | 0.78 | 0.65–1.39 | 0.49 ± 0.16 | 0.50 ± 0.16 | 0.37–0.58 | 0.000 |
Age | n1 | n2 | Difference | SE | Lower CI Limit | Upper CI Limit | Test Value | p-Value | |
---|---|---|---|---|---|---|---|---|---|
−ΔΔCt H19-BACT | |||||||||
37 | 18 | 18 | 0.00000 | 0.00030 | −0.00080 | 0.00080 | 0.06 | 0.955 | |
39 | 16 | 19 | 0.00010 | 0.00030 | −0.00070 | 0.00090 | 0.30 | 0.764 | |
45 | 19 | 14 | −0.00010 | 0.00030 | −0.00100 | 0.00090 | 0.23 | 0.819 | |
47 | 19 | 13 | 0.00010 | 0.00030 | −0.00100 | 0.00110 | 0.15 | 0.882 | |
50 | 21 | 12 | 0.00010 | 0.00040 | −0.00110 | 0.00130 | 0.32 | 0.756 | |
−ΔΔCt H19-GAPDH | |||||||||
37 | 18 | 18 | 0.00030 | 0.00030 | −0.00050 | 0.00120 | 1.20 | 0.244 | |
39 | 16 | 19 | 0.00040 | 0.00030 | −0.00040 | 0.00120 | 1.42 | 0.175 | |
45 | 19 | 14 | 0.00020 | 0.00030 | −0.00080 | 0.00110 | 0.49 | 0.630 | |
47 | 19 | 13 | 0.00020 | 0.00040 | −0.00080 | 0.00120 | 0.55 | 0.589 | |
50 | 21 | 12 | 0.00000 | 0.00040 | −0.00100 | 0.00110 | 0.06 | 0.950 |
Acromegaly (N/%) | Controls (N/%) | p | |
---|---|---|---|
Hypertension | 16 (50.0) | 5 (20.0) | 0.020 |
Dyslipidemia | 21 (65.6) | 10 (40.0) | 0.054 |
Diabetes | 9 (28.1) | 2 (8.0) | 0.090 |
Prediabetes | 8 (25.0) | 1 (4.0) | 0.063 |
Goiter | 21 (65.6) | 3 (12.0) | 0.000 |
Nephrolithiasis | 3 (9.4) | 0 | 0.248 |
Cholelithiasis | 12 (37.5) | 0 | 0.001 |
Colon polyps | 3 (9.4) | 0 | 0.248 |
Osteoporosis | 2 (6.25) | 1 (4.0) | 1.000 |
Pituitary insufficiency | 14 (43.75) | 6 (24.0) | 0.121 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rolla, M.; Jawiarczyk-Przybyłowska, A.; Kolačkov, K.; Zembska, A.; Bolanowski, M. Is H19 RNA a Useful Marker of Acromegaly and Its Complications? A Preliminary Study. Biomedicines 2023, 11, 1211. https://doi.org/10.3390/biomedicines11041211
Rolla M, Jawiarczyk-Przybyłowska A, Kolačkov K, Zembska A, Bolanowski M. Is H19 RNA a Useful Marker of Acromegaly and Its Complications? A Preliminary Study. Biomedicines. 2023; 11(4):1211. https://doi.org/10.3390/biomedicines11041211
Chicago/Turabian StyleRolla, Małgorzata, Aleksandra Jawiarczyk-Przybyłowska, Katarzyna Kolačkov, Agnieszka Zembska, and Marek Bolanowski. 2023. "Is H19 RNA a Useful Marker of Acromegaly and Its Complications? A Preliminary Study" Biomedicines 11, no. 4: 1211. https://doi.org/10.3390/biomedicines11041211